AGIO Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc (AGIO) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $296.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | Sell 10b5-1 | 7,866 | $37.69 | $296.5K | 54,645 −12.6% of holding | |
| Gheuens Sarah | Chief Medical Officer | Sell 10b5-1 | 500 | $37.52 | $18.8K | 54,645 −0.9% of holding | |
| Gheuens Sarah | Chief Medical Officer | Sell 10b5-1 | 1,489 | $37.53 | $55.9K | 54,645 −2.7% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.